Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia
NCT02075463 · GlaxoSmithKline · PHASE2 · terminated · last registry update 2026-08-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGLN2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-23Phase 3 first posted: Kyntra Bio, Roxadustat + Placebo (NCT07722988)
- 2026-07-07Also stopped (withdrawn): Peking Union Medical College Hospital, Roxadustat in combination with retinoic acid (NCT06020833)
- 2026-05-04Phase 3 first posted: Geoff Block, Epoetin alga (Epogen)/vadadustat (NCT07565701)
- 2025-12-23Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Daprodustat + Darbepoetin alfa (NCT07300111)
- 2025-12-09Also stopped (terminated): Peking Union Medical College Hospital, Roxadustat + Placebo (NCT05010460)
- 2025-11-10Results posted on the registry: GlaxoSmithKline, Daprodustat (NCT05682326)
- 2025-10-01Also stopped (withdrawn): Akebia Therapeutics, Vadadustat (NCT05082584)
- 2025-10-01Also stopped (withdrawn): Akebia Therapeutics, vadadustat (NCT05082571)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision